Leadership
Meet our team
Management
Guosong Liu, MD, PhD
Chief Executive Officer & Founder
Dr. Guosong Liu is a world-renowned neuroscientist whose pioneering research on brain magnesium has transformed our understanding of cognitive function and synaptic plasticity. As Founder and CEO of Neurocentria, Dr. Liu brings over 25 years of neuroscience expertise to leading the company's development of innovative therapies for neurological disorders. Prior to founding Neurocentria, Dr. Liu served as faculty at the Picower Institute for Learning and Memory at MIT for a decade and established the Center for Learning and Memory at Tsinghua University. His groundbreaking discoveries on magnesium's role in synaptic density regulation and cognitive enhancement led to the development of Magtein® (Magnesium L-threonate), which has demonstrated clinical efficacy in improving cognitive function in multiple human trials. Dr. Liu earned his Ph.D. in Neurophysiology from UCLA and completed his postdoctoral research at Stanford University, where he made significant contributions to understanding synaptic transmission in the central nervous system. His academic background combined with his translational research success uniquely positions him to guide Neurocentria's mission of developing novel therapeutics that target fundamental neurological mechanisms to address unmet medical needs.
Fei Mao,PhD
Chief Chemist & Founder
Dr. Fei Mao is the visionary founder and CEO of Biotium Inc., established in 2001, and co-founder of Neurocentria. With a Ph.D. in Inorganic Chemistry from the University of Oregon, he has transformed biological research through pioneering fluorescent technologies. His groundbreaking innovations include the industry-leading EvaGreen® dye and the exceptional CF® dye series. Dr. Mao's fluorescent membrane (FM) dyes have revolutionized neuroscience research by enabling real-time visualization of critical cellular processes. Under his leadership, Biotium has grown into a significant player in the life sciences market, with products used in thousands of laboratories worldwide and an estimated market value in the millions. Dr. Mao's unique expertise contributes significantly to Neurocentria across scientific, business, and leadership dimensions. His deep understanding of chemistry and neuronal function supports Neurocentria's pipeline and research initiatives, while his proven track record in commercialization and entrepreneurship strengthens the company's strategic vision.
Guy Bar-Klein, PhD
Executive Director of Research & Strategy
Dr. Guy Bar-Klein is a distinguished neuroscientist. His groundbreaking contributions to epilepsy research have led to novel treatment strategies for drug-resistant forms of the disorder. Most notably, Dr. Bar-Klein led the development of the first preventive treatment for epilepsy, a landmark achievement that shifted the paradigm from symptom management to disease prevention, offering hope for patients previously destined to develop this challenging condition. Simultaneously, his innovative work on the blood-brain barrier (BBB) has advanced our understanding of BBB dysfunction in neurological conditions.
Dr. Bar-Klein earned his Ph.D. from Ben Gurion University of the Negev and extended his research at the Johns Hopkins University School of Medicine and the Howard Hughes Medical Institute. He was also serving at Teva Pharmaceuticals, where he developed valuable expertise in budget management and information technology systems. At Neurocentria, Dr. Bar-Klein leads the clinical programs and regulatory affairs, where he navigates the complex landscape of drug development, clinical trials, and regulatory strategy.
Jason Weinger, PhD
Director of Scientific Operations
Scientific Advisory Board
Thomas C. Südhof, MD
Avram Goldstein Professor Investigator, Howard Hughes Medical Institute
Professor, Dept. of Molecular & Cellular Physiology and of Neurosurgery, Dept. of Neurology & Neurological Sciences and of Psychiatry & Behavioral Science, at Stanford University
Recipient of the Albert Lasker Basic Medical Research Award (2013)
Nobel Prize in Physiology or Medicine Winner (2013)
Jack Feldman, PhD
Distinguished Professor of Neurobiology at the University of California, Los Angeles (UCLA)
Recipient of the Hodgkin–Huxley–Katz Prize from the Physiological Society (2017)
Thomas Laughren, MD
Former Director, The Division of Psychiatry Products, Center for Drug Evaluation and Research, FDA